Timothy M. Clay

7.2k total citations · 1 hit paper
97 papers, 5.9k citations indexed

About

Timothy M. Clay is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Timothy M. Clay has authored 97 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Immunology, 42 papers in Oncology and 37 papers in Molecular Biology. Recurrent topics in Timothy M. Clay's work include Immunotherapy and Immune Responses (54 papers), T-cell and B-cell Immunology (28 papers) and CAR-T cell therapy research (22 papers). Timothy M. Clay is often cited by papers focused on Immunotherapy and Immune Responses (54 papers), T-cell and B-cell Immunology (28 papers) and CAR-T cell therapy research (22 papers). Timothy M. Clay collaborates with scholars based in United States, United Kingdom and Belgium. Timothy M. Clay's co-authors include H. Kim Lyerly, Michael A. Morse, Amy Hobeika, Takuya Osada, Michael I. Nishimura, Paul J. Mosca, Alain Delcayre, Jean‐Bernard Le Pecq, Xiao Yang and Donna Niedzwiecki and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

Timothy M. Clay

96 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer

2005 917 citations Michael A. Morse, Takuya Osada et al. Journal of Translational Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Timothy M. Clay United States	41	3.2k	2.6k	2.2k	796	747	97	5.9k
Jim Xiang Canada	41	2.9k 0.9×	2.7k 1.0×	1.5k 0.7×	507 0.6×	821 1.1×	186	5.4k
Mustafa Diken Germany	34	3.0k 0.9×	2.9k 1.1×	2.0k 0.9×	628 0.8×	323 0.4×	93	5.4k
Thorbald van Hall Netherlands	47	6.1k 1.9×	2.5k 0.9×	4.1k 1.9×	480 0.6×	401 0.5×	127	8.1k
Karine Breckpot Belgium	54	4.5k 1.4×	3.4k 1.3×	3.2k 1.5×	1.1k 1.4×	348 0.5×	170	7.6k
Willem W. Overwijk United States	49	7.1k 2.2×	2.7k 1.0×	4.9k 2.2×	931 1.2×	558 0.7×	112	9.6k
Amy Hobeika United States	34	2.5k 0.8×	2.0k 0.8×	1.7k 0.8×	318 0.4×	724 1.0×	90	4.2k
Thomas F. Gajewski United States	23	6.0k 1.9×	2.8k 1.1×	5.4k 2.5×	376 0.5×	1.0k 1.4×	33	9.4k
Jill E. Slansky United States	37	4.0k 1.2×	2.0k 0.7×	2.5k 1.1×	610 0.8×	298 0.4×	79	6.4k
Chiara Castelli Italy	46	5.8k 1.8×	4.4k 1.7×	4.8k 2.2×	488 0.6×	1.3k 1.7×	127	10.2k
Cornelis J.M. Melief Netherlands	41	5.4k 1.7×	4.5k 1.7×	1.9k 0.8×	428 0.5×	1.5k 2.0×	90	8.8k

Countries citing papers authored by Timothy M. Clay

Since Specialization

Citations

This map shows the geographic impact of Timothy M. Clay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy M. Clay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy M. Clay more than expected).

Fields of papers citing papers by Timothy M. Clay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy M. Clay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy M. Clay. The network helps show where Timothy M. Clay may publish in the future.

Co-authorship network of co-authors of Timothy M. Clay

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy M. Clay. A scholar is included among the top collaborators of Timothy M. Clay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy M. Clay. Timothy M. Clay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Osada, Takuya, Zachary C. Hartman, Jun-Ping Wei, et al.. (2018). Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. Breast Cancer Research. 20(1). 90–90. 15 indexed citations

Hamilton, Erika, Kimberly Blackwell, Amy Hobeika, et al.. (2012). Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion. Journal of Translational Medicine. 10(1). 28–28. 78 indexed citations

Osada, Takuya, Minyong Chen, Xiao Yang, et al.. (2011). Antihelminth Compound Niclosamide Downregulates Wnt Signaling and Elicits Antitumor Responses in Tumors with Activating APC Mutations. Cancer Research. 71(12). 4172–4182. 221 indexed citations

Hartman, Zachary C., Xiaoyi Yang, Oliver Glass, et al.. (2011). HER2 Overexpression Elicits a Proinflammatory IL-6 Autocrine Signaling Loop That Is Critical for Tumorigenesis. Cancer Research. 71(13). 4380–4391. 111 indexed citations

Hamilton, Erika, Timothy M. Clay, & Kimberly Blackwell. (2011). New Perspectives on Zoledronic Acid in Breast Cancer: Potential Augmentation of Anticancer Immune Response. Cancer Investigation. 29(8). 533–541. 23 indexed citations

Hartman, Zachary C., Takuya Osada, Oliver Glass, et al.. (2010). Ligand-Independent Toll-like Receptor Signals Generated by Ectopic Overexpression of MyD88 Generate Local and Systemic Antitumor Immunity. Cancer Research. 70(18). 7209–7220. 32 indexed citations

Hartman, Zachary C., Jun-Ping Wei, Takuya Osada, et al.. (2010). An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicty and Enhanced Therapeutic Efficacy without Oncogenicity. Clinical Cancer Research. 16(5). 1466–1477. 21 indexed citations

Morse, Michael A., Jun-Ping Wei, Zachary C. Hartman, et al.. (2009). Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. International Journal of Cancer. 126(12). 2893–2903. 19 indexed citations

Osada, Takuya, David S. Hsu, Scott A. Hammond, et al.. (2009). Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. British Journal of Cancer. 102(1). 124–133. 61 indexed citations

10.

Britten, Cedrik M., Sylvia Janetzki, Leah Ben‐Porat, et al.. (2009). Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunology Immunotherapy. 58(10). 1701–1713. 47 indexed citations

11.

Maecker, Holden T., Janice K. Payne, Michael A. Morse, et al.. (2008). Precision and linearity targets for validation of an IFNγ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunology. 9(1). 9–9. 55 indexed citations

12.

Hu, Zhenlin, Xiao Yang, Yunbo Liu, et al.. (2007). Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. Journal of Translational Medicine. 5(1). 34–34. 168 indexed citations

13.

Murad, Yanal, Timothy M. Clay, H. Kim Lyerly, & Michael A. Morse. (2007). CPG-7909 (PF-3512676, ProMune^®): toll-like receptor-9 agonist in cancer therapy. Expert Opinion on Biological Therapy. 7(8). 1257–1266. 44 indexed citations

14.

Langer, Lee, Timothy M. Clay, & Michael A. Morse. (2007). Update on anti-CTLA-4 antibodies in clinical trials. Expert Opinion on Biological Therapy. 7(8). 1245–1256. 59 indexed citations

15.

Osada, Takuya, et al.. (2006). Dendritic Cell-Based Immunotherapy. International Reviews of Immunology. 25(5-6). 377–413. 83 indexed citations

16.

Morse, Michael A., Smita K. Nair, David Boczkowski, et al.. (2002). The Feasibility and Safety of Immunotherapy with Dendritic Cells Loaded with CEA mRNA Following Neoadjuvant Chemoradiotherapy and Resection of Pancreatic Cancer. International Journal of Gastrointestinal Cancer. 32(1). 1–6. 75 indexed citations

17.

Lyerly, H. Kim, et al.. (2002). Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenes. Expert Opinion on Biological Therapy. 2(4). 353–360. 8 indexed citations

18.

Clay, Timothy M., Mary Custer, Paul J. Spiess, & Michael I. Nishimura. (1999). Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer. Pathology & Oncology Research. 5(1). 3–15. 17 indexed citations

19.

Clay, Timothy M., et al.. (1995). HLA‐DQB1 AND DQA1 MATCHING BY AMBIENT TEMPERATURE PCR‐SSCP. International Journal of Immunogenetics. 22(6). 467–478. 10 indexed citations

20.

Day, Sara, et al.. (1994). DR7‐Dw17 AND DR7‐DwDB1 HAPLOTYPES CONTAIN DIFFERENT ALLELES OF THE HLA‐DRB7 PSEUDOGENE. International Journal of Immunogenetics. 21(5). 383–386. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact